Inhibition of Platelet Aggregation and Clot Retraction by Kuwanon H

phospholipids degrade, inositol 1,4,5-trisphosphate is released into the cytoplasm, and stored calcium is released (3) , and the released calcium activates dependent enzymes that affect platelet integrin αIIb/β 3 .When platelet is acti-Objectives: Platelets are central to the development and progression of many forms of cardiovascular diseases, playing a dual role in hemostasis and thrombosis.Platelets recognize damaged blood vessels and quickly activate to form a hemostatic plug.Simultaneously, they can form clots, which can lead to cardiovascular diseases such as myocardial infarction and stroke.While various drugs have been developed to treat cardiovascular disease, we focused on prevention and explored various natural products.Among the various candidates, we discovered kuwanon H and analyzed the antiplatelet activity.Methods: To confirm the antiplatelet effect of kuwanon H, we conducted in vitro experiments using human platelets.Using a human platelet suspension, we observed platelet aggregation, calcium release, thromboxane A 2 synthesis, and integrin activity.We also examined the phosphorylation of platelet-related signaling molecules.Results: Kuwanon H inhibited platelet aggregation in a dose-dependent manner and suppressed Ca 2+ mobilization, dense granule secretion, thromboxane A 2 generation.To analyze the effects of kuwanon H on platelets, we analyzed the phosphorylation of cell signaling molecules related to platelet activation and kuwanon H effectively modulated the phosphorylation of signaling molecules associated with platelet activation.Conclusion: These findings suggest that kuwanon H may be a promising therapeutic compound for preventing abnormal platelet activation or thrombosis.